Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Nov 13 (Reuters) - Zealand Pharma ZELA.CO is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an interview with the company CEO. (Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)